Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence.

L'Huillier, Arnaud G; Pagano, Sabrina; Baggio, Stephanie; Meyer, Benjamin; Andrey, Diego O; Nehme, Mayssam; Guessous, Idris; Eberhardt, Christiane S; Huttner, Angela; Posfay-Barbe, Klara M; Yerly, Sabine; Siegrist, Claire-Anne; Kaiser, Laurent; Vuilleumier, Nicolas (2022). Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence. European journal of clinical investigation EJCI, 52(10), e13818. Wiley-Blackwell 10.1111/eci.13818

Preview

Text LHuillier_EurJClinInvest_2022.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (357kB) | Preview

BACKGROUND

SARS-CoV-2 infection triggers different auto-antibodies, including anti-apolipoprotein A-1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID-19, and the impact of AAA1 on the inflammatory response and symptoms persistence.

METHODS

All serologies were assessed at one, three, six, and twelve months in 193 hospital employees with COVID-19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient-reported COVID-19 symptoms persistence at 12 months. Interferon (IFN)-α and-γ production by AAA1-stimulated human monocyte-derived macrophages (HMDM) was assessed in vitro.

RESULTS

AAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID-19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti-SARS-COV2 serologies decreased, but remained significant. From the 3rd month on, AAA1 levels predicted persistent respiratory symptoms (area under the curves 0.72-0.74; p<0.001), independently of disease severity, age and gender (adjusted odds ratios 4.81-4.94; p=0.02), while anti-SARS-CoV-2 serologies did not. AAA1 increased IFN-α production by HMDMs (p=0.03), without affecting the IFN-γ response.

CONCLUSION

COVID-19 induces a marked though transient AAA1 response, independently predicting one-year persistence of respiratory symptoms. By increasing IFN-α response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID-19 risk stratification remains to be determined.

Interest & Impact

Downloads

218 since deposited on 23 May 2022
86 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item